Carvacrol improves blood lipid and glucose in rats with type 2 diabetes mellitus by regulating short-chain fatty acids and the GPR41/43 pathway
Yan Sun, Hai Qu, Xiaohong Niu, Ting Li, Lijuan Wang, Hairui Peng
Abstract
, high glucose (HG)-induced IEC-6 cells were treated with CAR, and optimal CAR concentration was determined. HG-induced IEC-6 cells were treated with SCFAs or/and GPR41/43 agonists. CAR significantly reduced blood lipid and glucose levels, improved tissue damage, and increased SCFA levels in feces and GPR41/43 expression in colonic tissues of T2DM rats. CAR also attenuated HG-induced apoptosis of IEC-6 cells and enhanced GPR41/43 expression. Overall, these findings suggest that CAR alleviates blood lipid and glucose abnormalities in T2DM rats by modulating SCFAs and the GPR41/43 pathway.
Topics & Concepts
DyslipidemiaInternal medicineEndocrinologyGut floraDiabetes mellitusType 2 Diabetes MellitusBlood sugarType 2 diabetesStreptozocinBlood lipidsMedicineChemistryCholesterolStreptozotocinBiochemistryNatural Antidiabetic Agents StudiesBiochemical Analysis and Sensing TechniquesCholesterol and Lipid Metabolism